# Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.

Study · id `cardio:ct-nct05933720` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05933720](<https://clinicaltrials.gov/study/NCT05933720>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05933720

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05933720. Non-randomized; no masking; primary purpose treatment. Start 2023-04-01 (actual); primary completion 2026-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05933720, source copy `cardio:ctgov-nct05933720-2023-07-06`, retrieved 2026-10-31)
- Started: 2023-04-01 (actual) (ClinicalTrials.gov record NCT05933720, source copy `cardio:ctgov-nct05933720-2023-07-06`, retrieved 2026-10-31)
- Primary completion: 2026-06-01 (anticipated) (ClinicalTrials.gov record NCT05933720, source copy `cardio:ctgov-nct05933720-2023-07-06`, retrieved 2026-10-31)
- Completion: 2026-09-01 (anticipated) (ClinicalTrials.gov record NCT05933720, source copy `cardio:ctgov-nct05933720-2023-07-06`, retrieved 2026-10-31)
- Countries: Russia (ClinicalTrials.gov record NCT05933720, source copy `cardio:ctgov-nct05933720-2023-07-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05933720-2023-07-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.
- Condition: Peripheral Arterial Occlusive Disease
- Intervention (Drug): Polypeptides
- Intervention (Device): Femoral-popliteal bypass grafting with a synthetic graft above the knee
- Intervention (Other): Routine conservative treatment
- Lead sponsor: Ryazan State Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: c41e7e82453fd6642fb10160f9ceb0af6a29d1ff3f5a8674057a27dcc27fc326
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
